Transplantation of PEGylated islets enhances therapeutic efficacy in a diabetic nonhuman primate model

Cherie L. Stabler, Jaime A. Giraldo, Dora M. Berman, Kerim M. Gattás-Asfura, Melissa A. Willman, Alexander Rabassa, James Geary, Waldo Diaz, Norma S. Kenyon, Norma S. Kenyon

Research output: Contribution to journalArticle

Abstract

Islet cell transplantation can lead to insulin independence, reduced hypoglycemia, and amelioration of diabetes complications in patients with type 1 diabetes. The systemic delivery of anti-inflammatory agents, while considered crucial to limit the early loss of islets associated with intrahepatic infusion, increases the burden of immunosuppression. In an effort to decrease the pharmaceutical load to the patient, we modified the pancreatic islet surface with long-chain poly(ethylene glycol) (PEG) to mitigate detrimental host-implant interactions. The effect of PEGylation on islet engraftment and long-term survival was examined in a robust nonhuman primate model via three paired transplants of dosages 4300, 8300, and 10 000 islet equivalents per kg body weight. A reduced immunosuppressive regimen of anti-thymocyte globulin induction plus tacrolimus in the first posttransplant month followed by maintenance with sirolimus monotherapy was employed. To limit transplant variability, two of the three pairs were closely MHC-matched recipients and received MHC-disparate PEGylated or untreated islets isolated from the same donors. Recipients of PEGylated islets exhibited significantly improved early c-peptide levels, reduced exogenous insulin requirements, and superior glycemic control, as compared to recipients of untreated islets. These results indicate that this simple islet modification procedure may improve islet engraftment and survival in the setting of reduced immunosuppression.

Original languageEnglish (US)
JournalAmerican Journal of Transplantation
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Islets of Langerhans Transplantation
Islets of Langerhans
Immunosuppression
Primates
Insulin
Transplants
Antilymphocyte Serum
Survival
Ethylene Glycol
Cell Transplantation
Tacrolimus
Sirolimus
Diabetes Complications
Immunosuppressive Agents
Type 1 Diabetes Mellitus
Hypoglycemia
Anti-Inflammatory Agents
Body Weight
Maintenance
Tissue Donors

Keywords

  • animal models: nonhuman primate
  • basic (laboratory) research/science
  • immunosuppression/immune modulation
  • immunosuppressive regimens
  • islet transplantation
  • islets of Langerhans
  • translational research/science

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

Transplantation of PEGylated islets enhances therapeutic efficacy in a diabetic nonhuman primate model. / Stabler, Cherie L.; Giraldo, Jaime A.; Berman, Dora M.; Gattás-Asfura, Kerim M.; Willman, Melissa A.; Rabassa, Alexander; Geary, James; Diaz, Waldo; Kenyon, Norma S.; Kenyon, Norma S.

In: American Journal of Transplantation, 01.01.2019.

Research output: Contribution to journalArticle

Stabler, Cherie L. ; Giraldo, Jaime A. ; Berman, Dora M. ; Gattás-Asfura, Kerim M. ; Willman, Melissa A. ; Rabassa, Alexander ; Geary, James ; Diaz, Waldo ; Kenyon, Norma S. ; Kenyon, Norma S. / Transplantation of PEGylated islets enhances therapeutic efficacy in a diabetic nonhuman primate model. In: American Journal of Transplantation. 2019.
@article{2801675bc16d4ab6ae0389e900660e94,
title = "Transplantation of PEGylated islets enhances therapeutic efficacy in a diabetic nonhuman primate model",
abstract = "Islet cell transplantation can lead to insulin independence, reduced hypoglycemia, and amelioration of diabetes complications in patients with type 1 diabetes. The systemic delivery of anti-inflammatory agents, while considered crucial to limit the early loss of islets associated with intrahepatic infusion, increases the burden of immunosuppression. In an effort to decrease the pharmaceutical load to the patient, we modified the pancreatic islet surface with long-chain poly(ethylene glycol) (PEG) to mitigate detrimental host-implant interactions. The effect of PEGylation on islet engraftment and long-term survival was examined in a robust nonhuman primate model via three paired transplants of dosages 4300, 8300, and 10 000 islet equivalents per kg body weight. A reduced immunosuppressive regimen of anti-thymocyte globulin induction plus tacrolimus in the first posttransplant month followed by maintenance with sirolimus monotherapy was employed. To limit transplant variability, two of the three pairs were closely MHC-matched recipients and received MHC-disparate PEGylated or untreated islets isolated from the same donors. Recipients of PEGylated islets exhibited significantly improved early c-peptide levels, reduced exogenous insulin requirements, and superior glycemic control, as compared to recipients of untreated islets. These results indicate that this simple islet modification procedure may improve islet engraftment and survival in the setting of reduced immunosuppression.",
keywords = "animal models: nonhuman primate, basic (laboratory) research/science, immunosuppression/immune modulation, immunosuppressive regimens, islet transplantation, islets of Langerhans, translational research/science",
author = "Stabler, {Cherie L.} and Giraldo, {Jaime A.} and Berman, {Dora M.} and Gatt{\'a}s-Asfura, {Kerim M.} and Willman, {Melissa A.} and Alexander Rabassa and James Geary and Waldo Diaz and Kenyon, {Norma S.} and Kenyon, {Norma S.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/ajt.15643",
language = "English (US)",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Transplantation of PEGylated islets enhances therapeutic efficacy in a diabetic nonhuman primate model

AU - Stabler, Cherie L.

AU - Giraldo, Jaime A.

AU - Berman, Dora M.

AU - Gattás-Asfura, Kerim M.

AU - Willman, Melissa A.

AU - Rabassa, Alexander

AU - Geary, James

AU - Diaz, Waldo

AU - Kenyon, Norma S.

AU - Kenyon, Norma S.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Islet cell transplantation can lead to insulin independence, reduced hypoglycemia, and amelioration of diabetes complications in patients with type 1 diabetes. The systemic delivery of anti-inflammatory agents, while considered crucial to limit the early loss of islets associated with intrahepatic infusion, increases the burden of immunosuppression. In an effort to decrease the pharmaceutical load to the patient, we modified the pancreatic islet surface with long-chain poly(ethylene glycol) (PEG) to mitigate detrimental host-implant interactions. The effect of PEGylation on islet engraftment and long-term survival was examined in a robust nonhuman primate model via three paired transplants of dosages 4300, 8300, and 10 000 islet equivalents per kg body weight. A reduced immunosuppressive regimen of anti-thymocyte globulin induction plus tacrolimus in the first posttransplant month followed by maintenance with sirolimus monotherapy was employed. To limit transplant variability, two of the three pairs were closely MHC-matched recipients and received MHC-disparate PEGylated or untreated islets isolated from the same donors. Recipients of PEGylated islets exhibited significantly improved early c-peptide levels, reduced exogenous insulin requirements, and superior glycemic control, as compared to recipients of untreated islets. These results indicate that this simple islet modification procedure may improve islet engraftment and survival in the setting of reduced immunosuppression.

AB - Islet cell transplantation can lead to insulin independence, reduced hypoglycemia, and amelioration of diabetes complications in patients with type 1 diabetes. The systemic delivery of anti-inflammatory agents, while considered crucial to limit the early loss of islets associated with intrahepatic infusion, increases the burden of immunosuppression. In an effort to decrease the pharmaceutical load to the patient, we modified the pancreatic islet surface with long-chain poly(ethylene glycol) (PEG) to mitigate detrimental host-implant interactions. The effect of PEGylation on islet engraftment and long-term survival was examined in a robust nonhuman primate model via three paired transplants of dosages 4300, 8300, and 10 000 islet equivalents per kg body weight. A reduced immunosuppressive regimen of anti-thymocyte globulin induction plus tacrolimus in the first posttransplant month followed by maintenance with sirolimus monotherapy was employed. To limit transplant variability, two of the three pairs were closely MHC-matched recipients and received MHC-disparate PEGylated or untreated islets isolated from the same donors. Recipients of PEGylated islets exhibited significantly improved early c-peptide levels, reduced exogenous insulin requirements, and superior glycemic control, as compared to recipients of untreated islets. These results indicate that this simple islet modification procedure may improve islet engraftment and survival in the setting of reduced immunosuppression.

KW - animal models: nonhuman primate

KW - basic (laboratory) research/science

KW - immunosuppression/immune modulation

KW - immunosuppressive regimens

KW - islet transplantation

KW - islets of Langerhans

KW - translational research/science

UR - http://www.scopus.com/inward/record.url?scp=85075029483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075029483&partnerID=8YFLogxK

U2 - 10.1111/ajt.15643

DO - 10.1111/ajt.15643

M3 - Article

C2 - 31597005

AN - SCOPUS:85075029483

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

ER -